BioSpace News Archive

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (cisplatin plus 5-fluorouracil [5-FU]) for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction (GEJ) cancer

Bristol Myers Squibb (NYSE: BMY) today announced primary results from CheckMate -649, the pivotal Phase 3 trial in which first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival (OS) and progression-free survival (PFS) of patients with unresectable advanced or metastatic gastric cancer,

Pathline Labs, a leading provider of sub-specialized anatomic pathology, has expanded its COVID-19 testing capabilities across the country while maintaining a 24-36-hour turnaround time for processing.

Bristol Myers Squibb (NYSE: BMY) today announced first results from the Phase 3 CheckMate -577 trial in which adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS), the trial’s primary endpoint,

As mounting “case” numbers are defining “hot spots” and directing public policy, San Antonio ophthalmologist Kristin S. Held, M.D., president of the Association of American Physicians and Surgeons, calls for a careful analysis of the statistics in the fall issue of the Journal of American Physicians and Surgeons.

The Centers for Disease Control and Prevention (CDC), which according to its website is “recognized as the nation’s premiere health promotion, prevention and preparedness agency,” is playing a leading role in response to the COVID-19 pandemic. In the fall issue of the Journal of American Physicians and Surgeons , editor-in-c

More than 30 preeminent experts to present virtually; vast degree of structural disease change, high speed of cancer evolution, rarely considered until now [21-September-2020] BOSTON , Sept. 21, 2020 /PRNewswire/ -- Evolutionary processes have made cancer supremely difficult to treat and cure – but evolutionary thinking could hold the fundamental keys to stopping ca

Patients suffering from chronic and acute pain disorders will benefit from a convenient, discreet, and easy-to-use device delivering a novel alternative to opioid-based pain management.

Aziyo Biologics, Inc. (“Aziyo”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors. Maybell

Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases, today announced the closing of its initial public offering of 14,089,314 shares of its common stock at an initial public offering price of $19.00 per share, including 1,837,736 additional shares of common stock issued upon the exercise in full by the underwriters of their